Alpha Cognition (NASDAQ:ACOG) Issues Earnings Results, Beats Expectations By $0.04 EPS

Alpha Cognition (NASDAQ:ACOG) posted its quarterly earnings data on Thursday. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04, Zacks reports. Alpha Cognition had a negative net margin of 232.23% and a negative return on equity of 62.07%. The firm had revenue of $3.53 million during the quarter, compared to analyst estimates of $3.42 million.

Here are the key takeaways from Alpha Cognition’s conference call:

• ZUNVEYL commercialization accelerated in Q1 2026, with net product revenue rising 40% sequentially to $3.5 million and March delivering the strongest demand month since launch, with April said to be even stronger.
• Commercial adoption metrics improved across the board: bottles dispensed rose 23%, active HCP writers increased to 1,060, and nursing homes with prescriptions grew 25%, while repeat prescribing and repeat facility orders remained strong.
• The company reiterated its 2026 operating expense guidance of $54 million to $58 million and said it remains on track to reach operating profitability in 2027, supported by a $54.2 million cash balance and no debt.
• Alpha Cognition said its real-world evidence studies are advancing faster than expected, with BEACON enrollment expected to finish this quarter and top-line data due by early Q3, while CONVERGE and RESOLVE are also set to progress in 2026.
• The company strengthened its intellectual property around ZUNVEYL with two new U.S. patents extending protection through 2045, and it highlighted a large addressable opportunity for its traumatic brain injury program.

Alpha Cognition Trading Up 6.0%

ACOG traded up $0.34 during trading on Friday, hitting $6.02. The stock had a trading volume of 96,130 shares, compared to its average volume of 36,966. The firm has a market cap of $131.08 million, a PE ratio of -4.46 and a beta of 2.38. Alpha Cognition has a 12 month low of $4.50 and a 12 month high of $11.54. The company has a 50 day simple moving average of $6.07 and a 200-day simple moving average of $5.92.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ACOG shares. Craig Hallum started coverage on shares of Alpha Cognition in a research note on Friday, April 17th. They issued a “buy” rating and a $14.00 price objective for the company. Wall Street Zen lowered shares of Alpha Cognition from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Alpha Cognition in a research note on Monday, April 27th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Alpha Cognition has an average rating of “Buy” and an average price target of $16.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Ikarian Capital LLC raised its holdings in Alpha Cognition by 11.6% in the 4th quarter. Ikarian Capital LLC now owns 1,056,259 shares of the company’s stock worth $6,866,000 after acquiring an additional 110,000 shares during the period. Sphera Funds Management LTD. raised its holdings in Alpha Cognition by 67.6% in the 4th quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company’s stock worth $3,690,000 after acquiring an additional 228,864 shares during the period. Opaleye Management Inc. raised its holdings in Alpha Cognition by 1,698.5% in the 4th quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company’s stock worth $13,460,000 after acquiring an additional 1,955,642 shares during the period. Cantor Fitzgerald L. P. bought a new position in Alpha Cognition in the 4th quarter worth $1,062,000. Finally, AWM Investment Company Inc. raised its holdings in Alpha Cognition by 52.6% in the 4th quarter. AWM Investment Company Inc. now owns 1,672,168 shares of the company’s stock worth $10,869,000 after acquiring an additional 576,516 shares during the period.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.